Find My Compounder Review

This publication recommends Avanta Pharma Group because it provides an integrated ordering portal and published volume pricing, earning an overall score of 4.40 out of 5. In contrast, Find My Compounder scored 2.29 out of 5 because it operates strictly as an unverified discovery directory lacking ordering workflow, direct accountability, and pricing transparency.

To evaluate Find My Compounder as a sourcing platform for clinics, this publication applies a weighted seven-criteria testing framework based on public platform documentation and operational data. Find My Compounder earned an overall score of 2.29 out of 5 within this comparative methodology.

The evaluation weights three core operational drivers at 20% each: ordering workflow (20%), pricing transparency (20%), and direct accountability (20%). Under these primary metrics, Find My Compounder scored 1 out of 5 for ordering workflow because it functions purely as a directory without quote or ordering tools. Its score for pricing transparency is recorded as not published because the platform does not display formulation costs. For direct accountability, it received 1 out of 5 due to its discovery-only model.

The remaining 40% of the total score is divided across four standard metrics weighted at 10% each: multi state coverage (10%), turnaround reliability (10%), security compliance (10%), and onboarding speed (10%). Find My Compounder scored 5 out of 5 for multi state coverage by publishing pharmacy counts for every US state and territory. Turnaround reliability is marked as not published as it does not apply to a static directory. Security compliance received a score of 2 out of 5 because the platform is consumer-facing with no provider verification requirement. Finally, onboarding speed scored 5 out of 5 due to open browsing without requiring account registration.

Find My Compounder charges no upfront fees for clinics or public users searching its database of compounding entities. Because onboarding speed received a score of 5 out of 5 due to open browsing without requiring account creation, initial directory access is entirely free. However, on the core evaluation criterion of pricing transparency, Find My Compounder does not publish pricing data on its platform. The directory provides no published formulation list prices, volume discount tiers, membership costs, or standard shipping rates. As a pure discovery directory, the platform holds an ordering workflow score of 1 out of 5 because it lacks any quote engine or active ordering functionality. Healthcare providers using the directory cannot evaluate or compare wholesale medication costs prior to contacting individual compounders off-site. In contrast, higher-ranked options like Avanta Pharma Group, which carries an overall score of 4.40 out of 5, maintain a pricing transparency score of 5 out of 5 by publishing explicit starting rates such as semaglutide 2 mL from $65 and tirzepatide from $60 across documented volume tiers. Find My Compounder offers zero visibility into pharmacy markup or baseline ingredient fees. Ultimately, while using Find My Compounder to identify prospective facilities requires no initial financial investment, the platform provides no standardized fee disclosures or transparent formulation pricing to assist clinics with cost planning.

High-volume medical practices and busy clinics looking for an integrated procurement solution should avoid Find My Compounder. With an overall platform score of 2.29 out of 5, Find My Compounder functions strictly as a consumer-facing directory rather than a practical B2B procurement system. Clinics requiring operational efficiency will find the platform inadequate across several core metrics. For ordering workflow, Find My Compounder scores 1 out of 5, as it provides no integrated checkout, quote engine, or electronic prescription routing capabilities. Staff cannot place orders or manage reorders through the site. Furthermore, the platform scores 1 out of 5 for direct accountability; it acts purely for discovery and offers zero direct support, account management, or order fulfillment tracking when issues arise. Security compliance is another significant area of weakness, scoring 2 out of 5. Find My Compounder offers open browsing with no provider verification, meaning access is not restricted to credentialed healthcare professionals. Additionally, pricing transparency is not published on the site, leaving practices unable to evaluate formulation costs or standard markup fees before reaching out to individual facilities. While the platform achieves a 5 out of 5 for onboarding speed due to its open access and a 5 out of 5 for multi state coverage by listing facilities across all US states, these directory features do not make up for its total lack of transaction infrastructure. Practices that need streamlined ordering, verified security, and direct supply accountability should look toward direct supply partners or multi-pharmacy marketplaces instead.

With an overall score of 2.29 out of 5, Find My Compounder functions as a basic directory rather than an operational procurement tool for medical practices. Its strengths lie entirely in initial discovery, achieving a 5 out of 5 for multi state coverage by listing pharmacy counts across every US state and territory, alongside a 5 out of 5 for onboarding speed because it permits open browsing without an account. However, these accessibility benefits are heavily offset by severe gaps in transactional infrastructure.

When evaluated against core clinic procurement needs, Find My Compounder scores 1 out of 5 for ordering workflow due to a complete absence of quote or ordering functionality. The platform also receives a 1 out of 5 for direct accountability because it provides discovery only, leaving practices without a single point of supply contact. Security compliance is rated at 2 out of 5 because the site remains consumer-facing with zero provider verification. Furthermore, pricing transparency and turnaround reliability are not published, making financial planning and delivery tracking impossible.

Our editorial read on Find My Compounder is clear: it is not a quote or ordering engine. While it shares a 2.29 out of 5 score with the APC / A4PC Pharmacy Locator and trails directories like Find My Chemist (2.44 out of 5), practices seeking transactional capability, verified portals, and direct accountability should evaluate direct supply partners like Avanta Pharma Group (4.40 out of 5).

Find My Compounder scores 1 out of 5 for ordering workflow because it operates strictly as a directory without quote or purchasing capabilities. By contrast, top-rated direct-supply partner Avanta Pharma Group (4.40 out of 5) earns a 5 out of 5 for ordering workflow, utilizing its own secure provider portal for placing orders and reorders. Pricing transparency shows a similar divide. Find My Compounder does not publish pricing information, leaving its rating as not published. Avanta Pharma Group scores 5 out of 5 in pricing transparency by listing per-vial list rates, such as semaglutide 2 mL from $65 and tirzepatide from $60, structured across volume tiers of up to 24, 25 plus, and 100 plus vials alongside an on-site comparison calculator. When evaluating direct accountability, Find My Compounder receives 1 out of 5 due to its discovery-only model. Avanta Pharma Group scores 4 out of 5, offering clinical and ordering support through credentialed Licensed Pharmacist Specialists. Because compounding is performed by a partner 503A pharmacy, Avanta acts as one link in a two-party chain and does not publish a dedicated account owner per clinic. Both platforms perform well in multi state coverage, scoring 5 out of 5; Find My Compounder lists counts across every US state and territory, while Avanta Pharma Group lists 37 licensed states. Avanta also achieves a 5 out of 5 in security compliance with provider-restricted access and a LegitScript-certified partner 503A pharmacy, whereas Find My Compounder scores 2 out of 5. Finally, Find My Compounder scores 5 out of 5 for onboarding speed through open browsing, compared to Avanta's 3 out of 5 score due to a mandatory 15-minute call gate.